Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Simons Foundation Autism Research Initiative, Simons Institute for the Developing Brain, The Patrick Wild Centre
- License Information
-
More Information
Article History
Received: 22 March 2021
Revised: 1 December 2021
Accepted: 12 January 2022
First Online: 24 January 2022
Competing interests
: Andrew Stanfield has received grant funding from Novartis and Roche, including for trials of mGluR5 antagonists in fragile X syndrome. Aisling Kenny and Damien Wright declare no conflict of interest.
